CN102058604A - Drug composition containing dienogest and estradiol valerate and preparation method thereof - Google Patents
Drug composition containing dienogest and estradiol valerate and preparation method thereof Download PDFInfo
- Publication number
- CN102058604A CN102058604A CN2009102381914A CN200910238191A CN102058604A CN 102058604 A CN102058604 A CN 102058604A CN 2009102381914 A CN2009102381914 A CN 2009102381914A CN 200910238191 A CN200910238191 A CN 200910238191A CN 102058604 A CN102058604 A CN 102058604A
- Authority
- CN
- China
- Prior art keywords
- dienogest
- estradiol valerate
- preparation
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a drug composition containing dienogest and estradiol valerate and a preparation method thereof. The composition takes dienogest and estradiol valerate as active ingredients, and the pharmaceutically acceptable auxiliary materials are added, thus the in-vitro dissolution is complete, the stability is good, the preparation process is simple and the industrial production is easy to realize.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that contains dienogest and estradiol valerate and preparation method thereof.
Background technology
Progestogen are the important chemical substances of a class, mainly are by ovary and corpus luteum secretion.The dependent interaction of progestogen mediations be on the basis of estrogen action, makes that endometrium continues to thicken, congested, glandular hyperplasia and branch, for blastocyst is implanted and embryo support implantation, promotion inner membrance basal cell are divided into Tui Mo and prepare.Add with progestogen in the time of owing to the discovery complementing estrogen and also can protect endometrium the eighties in 20th century, reduces the sickness rate of carcinoma of endometrium, can be used to eliminate the osteoporotic generation of menopausal women symptom, bone density improving and reduction clinically.
Dienogest can combine with progesterone receptor fully and not with other steroid receptors cross reaction, when therapeutic dose, do not have androgen, estrogen and glucocorticoid effect, metabolism and blood pressure are not made significant difference, can not offset the protective effect of estrogen to blood vessel wall.In recent years, dienogest is also receiving much concern aspect the anti-male fertility effect.Estradiol valerate is a kind of long-acting derivatives of estradiol, can not only alleviate the symptoms of menopause that causes because of estrogen deficiency, and postmenopausal osteoporosis is had the excellent prevention effect.At present, estradiol valerate has been widely used in clinical, and has obtained very good curative effect.
CN100462078C discloses a kind of compound estradiol valerate tablet and preparation method thereof, and wherein estradiol valerate adds with the form of superfine powder.Raw material can significantly improve the dissolution of medicine behind micronization, but loss is bigger, for the higher raw material of prices such as dienogest and estradiol valerate, adopts this technology can cause a large amount of losses of raw material, will certainly increase the production cost of enterprise.In addition, the not all production unit acceptable of special installation of micronization needs.For fear of above problem, and it is actual in conjunction with producing, the applicant utilizes pharmaceutically acceptable solvent that dienogest and estradiol valerate are prepared as solution, so not only preparation technology is simple, and medicine can be evenly dispersed in the compositions, thereby guaranteed the dissolution and the uniformity of dosage units of medicine.
Summary of the invention
The objective of the invention is to disclose a kind of pharmaceutical composition that contains dienogest and estradiol valerate and preparation method thereof, what be specifically related to is to be active component with dienogest and estradiol valerate, add acceptable accessories, wherein said composition exists with tablet, oral cavity disintegration tablet, granule, capsule form, not only external stripping fully, have good stability, and preparation technology is simple, is highly susceptible to suitability for industrialized production, can be used for the estrogenic succedaneum behind the postmenopausal women.
Described dienogest and estradiol valerate are to add with the solution form after being dissolved in certain solvent.
The solvent of described active component is selected from ethanol or dehydrated alcohol.
Contain gas-producing disintegrant in the described compositions.
Described gas-producing disintegrant is selected from the compositions of citric acid or tartaric acid and sodium bicarbonate or sodium carbonate.
Described compositions existence form is tablet, oral cavity disintegration tablet, granule, capsule.
The specific embodiment
The existence form of embodiment 1 this embodiment is a tablet
Preparation technology:
1. the dienogest and the estradiol valerate that take by weighing recipe quantity are dissolved in the adequate amount of ethanol, and be standby;
2. prepare 10% starch slurry as binding agent, standby;
3. with the solution mixing of lactose and active component, fling to ethanol, again with microcrystalline Cellulose, citric acid by the equivalent principle mixing that progressively increases;
4. add 10% starch slurry system soft material, 16 mesh sieves are granulated;
5.50 ℃ be dried to determination of water value L.O.D (90 ℃, 5min)＜3.5%;
6.20 mesh sieve granulate;
7. add sodium bicarbonate and magnesium stearate, mixing in proportion;
8. Φ 6mm plane chamfering stamping.
The existence form of embodiment 2 these embodiment is an oral cavity disintegration tablet
Preparation technology:
1. the dienogest and the estradiol valerate that take by weighing recipe quantity are dissolved in the adequate amount of ethanol, and be standby;
2. prepare the alcoholic solution (ethanol: water=50: 50), standby of 15% 30 POVIDONE K 30 BP/USP 30;
3. with the solution mixing of mannitol and active component, fling to ethanol, again with ethyl cellulose-RT-10, tartaric acid by the equivalent principle mixing that progressively increases,
4. add binding agent system soft material, 16 mesh sieves are granulated;
5.50 ℃ be dried to determination of water value L.O.D (90 ℃, 5min)＜3.5%;
9.24 mesh sieve granulate;
10. add sodium carbonate, acesulfame potassium and magnesium stearate, mixing in proportion;
11. Φ 6mm plane chamfering stamping.
The existence form of embodiment 3 these embodiment is a granule
Preparation technology:
1. the dienogest and the estradiol valerate that take by weighing recipe quantity are dissolved in the adequate amount of ethanol, and be standby;
2. prepare the alcoholic solution (ethanol: water=50: 50), standby of 15% 30 POVIDONE K 30 BP/USP 30;
3. with the solution mixing of mannitol and active component, fling to ethanol, again with microcrystalline Cellulose, tartaric acid by the equivalent principle mixing that progressively increases,
4. add binding agent system soft material, 14 mesh sieves are granulated;
5.50 ℃ be dried to determination of water value L.O.D (90 ℃, 5min)＜3.5%;
6.16 mesh sieve granulate;
7. add sodium carbonate, flavoring orange essence, mixing in proportion.
The existence form of embodiment 4 these embodiment is a capsule
Preparation technology:
1. the dienogest and the estradiol valerate that take by weighing recipe quantity are dissolved in the adequate amount of ethanol, and be standby;
2. prepare 10% starch slurry as binding agent, standby;
3. with the solution mixing of mannitol and active component, fling to ethanol, again with microcrystalline Cellulose, citric acid by the equivalent principle mixing that progressively increases,
4. add binding agent system soft material, 18 mesh sieves are granulated;
5.50 ℃ be dried to determination of water value L.O.D (90 ℃, 5min)＜3.5%;
6.30 mesh sieve granulate;
7. add sodium bicarbonate, magnesium stearate, mixing in proportion;
8.4# capsule shells is filled.
The sample of 5 couples of embodiment of embodiment, 1,2,3,4 preparations carries out dissolution determination
Sample 1,2,3,4 to embodiment 1,2,3,4 preparations carries out determination of dissolution rate respectively, wherein dissolution adopts " second method in 2005 editions two appendix XC dissolution methods of Chinese pharmacopoeia, dissolution medium is the 0.5%SDS aqueous solution of 900mL, and rotating speed is 75r/min, the 30min sampling.
Embodiment 6 raw materials adopt micronization and two kinds of forms of solution to add respectively, and the sample of preparation carries out dissolution determination
Adopt the technical scheme of embodiment 1, the feedstock production sample that adds micronization, two kinds of forms of solution respectively is 1,2, and the determination of dissolution rate method is identical with embodiment 5.
As seen from the above table, adopt the dissolution of sample of the feedstock production of two kinds of forms not have marked difference respectively.
The sample of 7 couples of embodiment of embodiment, 1,2,3,4 preparations carries out Determination of Content Uniformity, and its result is as follows:
According to " A+1.80S≤15 under 2005 editions two appendix XE items of Chinese pharmacopoeia, the uniformity of dosage units of each preparation is all good.
The oral cavity disintegration tablet of 8 couples of embodiment of embodiment, 2 preparations carries out the mensuration of disintegration
Assay method: select 6 experimenters, oral cavity disintegration tablet is placed on the tongue and timing, last Hubei Province and tongue last slice slightly rub, and stop timing when no solid or grittiness in mouth, and the result is as follows:
The sample of 9 couples of embodiment of embodiment, 1 preparation carries out accelerated stability test, and the result is as follows:
Hence one can see that, and this kind contains the sample of preparation of pharmaceutical compositions of dienogest and estradiol valerate, and not only dissolution height, content are even, quicken 6 months good stabilities, and cost are low, have development and application and are worth.
Claims (6)
1. pharmaceutical composition that contains dienogest and estradiol valerate and preparation method thereof is characterized in that said composition is is active component with dienogest and estradiol valerate, adds acceptable accessories.
2. pharmaceutical composition according to claim 1 is characterized in that described dienogest and estradiol valerate are to add with the solution form after being dissolved in certain solvent.
3. pharmaceutical composition according to claim 2 is characterized in that the solvent of described active component is selected from ethanol or dehydrated alcohol.
4. pharmaceutical composition according to claim 1 is characterized in that containing gas-producing disintegrant in the described compositions.
5. pharmaceutical composition according to claim 4 is characterized in that described gas-producing disintegrant is selected from the compositions of citric acid or tartaric acid and sodium bicarbonate or sodium carbonate.
6. pharmaceutical composition according to claim 1 is characterized in that said composition exists with tablet, oral cavity disintegration tablet, granule, capsular form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102381914A CN102058604A (en) | 2009-11-17 | 2009-11-17 | Drug composition containing dienogest and estradiol valerate and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102381914A CN102058604A (en) | 2009-11-17 | 2009-11-17 | Drug composition containing dienogest and estradiol valerate and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102058604A true CN102058604A (en) | 2011-05-18 |
Family
ID=43994230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102381914A Pending CN102058604A (en) | 2009-11-17 | 2009-11-17 | Drug composition containing dienogest and estradiol valerate and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102058604A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105979935A (en) * | 2013-12-12 | 2016-09-28 | 多内斯塔生物科学股份有限公司 | Orally disintegrating solid dosage unit containing an estetrol component |
| US10660903B2 (en) | 2015-06-18 | 2020-05-26 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
| US10844088B2 (en) | 2011-07-19 | 2020-11-24 | Estetra Sprl | Process for the preparation of estetrol |
| US10888518B2 (en) | 2015-06-18 | 2021-01-12 | Estetra Sprl | Orodispersible tablet containing estetrol |
| US10894014B2 (en) | 2015-06-18 | 2021-01-19 | Estetra Sprl | Orodispersible tablet containing Estetrol |
| US11053273B2 (en) | 2011-06-01 | 2021-07-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
| US11053274B2 (en) | 2011-06-01 | 2021-07-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
| US11147771B2 (en) | 2015-06-18 | 2021-10-19 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
| WO2022069956A1 (en) * | 2020-09-29 | 2022-04-07 | Millicent Pharma Limited | Orodispersible formulations |
| US11452733B2 (en) | 2018-04-19 | 2022-09-27 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
| US11484539B2 (en) | 2018-04-19 | 2022-11-01 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
| US11896602B2 (en) | 2016-08-05 | 2024-02-13 | Estetra Srl | Method for preventing pregnancy |
-
2009
- 2009-11-17 CN CN2009102381914A patent/CN102058604A/en active Pending
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11053273B2 (en) | 2011-06-01 | 2021-07-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
| US11053274B2 (en) | 2011-06-01 | 2021-07-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
| US10844088B2 (en) | 2011-07-19 | 2020-11-24 | Estetra Sprl | Process for the preparation of estetrol |
| CN105979935B (en) * | 2013-12-12 | 2019-07-26 | 多内斯塔生物科学股份有限公司 | Mouth comprising estetrol component collapses solid dosage unit |
| CN105979935A (en) * | 2013-12-12 | 2016-09-28 | 多内斯塔生物科学股份有限公司 | Orally disintegrating solid dosage unit containing an estetrol component |
| US11147771B2 (en) | 2015-06-18 | 2021-10-19 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
| US10894014B2 (en) | 2015-06-18 | 2021-01-19 | Estetra Sprl | Orodispersible tablet containing Estetrol |
| US10888518B2 (en) | 2015-06-18 | 2021-01-12 | Estetra Sprl | Orodispersible tablet containing estetrol |
| US10660903B2 (en) | 2015-06-18 | 2020-05-26 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
| US11793760B2 (en) | 2015-06-18 | 2023-10-24 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
| US11957694B2 (en) | 2015-06-18 | 2024-04-16 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
| US11964055B2 (en) | 2015-06-18 | 2024-04-23 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
| US11896602B2 (en) | 2016-08-05 | 2024-02-13 | Estetra Srl | Method for preventing pregnancy |
| US11452733B2 (en) | 2018-04-19 | 2022-09-27 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
| US11484539B2 (en) | 2018-04-19 | 2022-11-01 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
| TWI801561B (en) * | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | Compounds and their uses for alleviating menopause-associated symptoms |
| US11666585B2 (en) | 2018-04-19 | 2023-06-06 | Estetra Srl | Compounds and their uses for alleviating menopause-associated symptoms |
| WO2022069956A1 (en) * | 2020-09-29 | 2022-04-07 | Millicent Pharma Limited | Orodispersible formulations |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102058604A (en) | Drug composition containing dienogest and estradiol valerate and preparation method thereof | |
| NO332726B1 (en) | Preparation with oestrogenic cyclodextrin complex, process for preparing the same and process for improving estrogen stability and use of the preparation | |
| EP2734193B1 (en) | Tablet containing dehydroepiandrosterone (dhea) | |
| CN107810001A (en) | Orodispersible tablet containing E4 | |
| CN107750157A (en) | Orodispersible tablet containing E4 | |
| CZ42596A3 (en) | Pharmaceutical composition for oral administration containing micro milled prgesterone and polyethylene glycol together with en excipient and process for preparing thereof | |
| CN102114001A (en) | Orally administered solid preparation containing tolvaptan | |
| CN101099724A (en) | Micronization femara and its composition | |
| CN101711751A (en) | Febuxostat dispersing tablet preparation and preparation method thereof | |
| EP1121375B1 (en) | High purity compound (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one | |
| CN101732235B (en) | Method for preparing solid dispersion of tamoxifen citrate | |
| CA2782498C (en) | Tablet composition containing kampo medicinal extract and its manufacturing process | |
| CN112294883B (en) | Stomach-strengthening tablet medicinal preparation and preparation method thereof | |
| NO780799L (en) | PROCEDURE FOR PREPARING A SOLID STEROID PREPARATION | |
| CN102552920B (en) | Entecavir-containing medicinal composition and preparation method thereof | |
| CN101711743B (en) | Febuxostat dry suspension and preparation method thereof | |
| CN103505740A (en) | Cyclodextrin mifepristone clathrate compound, preparation method thereof, and pharmaceutical composition containing clathrate compound | |
| CN102349882A (en) | Medicinal composition containing trandolapril and preparation process thereof | |
| CN114569567B (en) | Stable norethindrone diacetate ethinyl estradiol compound tablet and preparation method thereof | |
| CN101926782B (en) | Oral solid drug compound containing dienogest | |
| CN100551369C (en) | A kind of slow releasing preparation that contains cilostazol and preparation method thereof | |
| CN1325054C (en) | Cyclic dextrin inclusion compound of mintpress hydrochloride and its preparing method | |
| CN102274235B (en) | New contraceptive medicinal composition and preparation method thereof | |
| CN102988322A (en) | Arginine ibuprofen tablet and preparation method thereof | |
| CN103893144A (en) | Oral progestin composition for improving dissolution and preparation method of oral progestin composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110518 |